NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites ...

Pfiz­er said its ex­per­i­men­tal an­ti-PD-1 drug best­ed the cur­rent stan­dard of care in a type of blad­der can­cer where ...

Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...

Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...

With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.